Target

EZH2

Histone-lysine N-methyltransferase EZH2

10open trials
20trials in total
176publications
0researchers

Diseases

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Publication
Methionine restriction inhibits EZH2-mediated GSDMD methylation to promote pyroptosis in prostate cancer.
6 Nov 2026· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publication
IDO1 methylation by EZH2 confers resistance to its targeted therapy in colorectal cancer through tryptophan-kynurenine metabolic rewiring.
5 Nov 2026· Cell reports· PUBMED
Publication
Retraction Note: Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.
4 Nov 2026· Cell death & disease· PUBMED
Publication
Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation.
26 Oct 2026· Leukemia & lymphoma· PUBMED
Publication
EZH2 in Ovarian Cancer: Mechanistic Dependencies, Therapeutic Platforms and Translational Combinations.
15 Oct 2026· Mini reviews in medicinal chemistry· PUBMED
Publication
EZH2 Inhibition and Myeloid Risk: A Feature of On-Target Biology.
15 Oct 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
EZH2 mutation status predicts inferior outcomes after bendamustine-based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study.
15 Oct 2026· HemaSphere· PUBMED
Publication
Epigenetically silencing gluconeogenic enzyme PCK1 by EZH2 promotes renal tubulointerstitial fibrosis.
14 Oct 2026· Molecular biomedicine· PUBMED
Publication
Engineered mesenchymal stem cell-derived small extracellular vesicles delivering miR-124 suppress colorectal cancer progression through EZH2 downregulation and attenuation of STAT3 signaling.
8 Oct 2026· Medical oncology (Northwood, London, England)· PUBMED
Publication
EZH2 Inhibition Induces a Metabolic Stress Response Sensitizing Triple-Negative Breast Cancer to Glutaminase Targeting.
2 Oct 2026· Cancer research· PUBMED
Publication
Correction: EZH2-Deficient T-Cell Acute Lymphoblastic Leukemia is Sensitized to CHK1 Inhibition Through Enhanced Replication Stress.
1 Oct 2026· Cancer discovery· PUBMED
Publication
EZH2-dependent phenotypic plasticity reveals TTP-associated and mTORC1 therapeutic vulnerabilities in lethal prostate cancer.
30 Sept 2026· Cell reports. Medicine· PUBMED
Trial
AXT-1003 Combination With Enzalutamide in Participants With mCRPC
24 Sept 2026· PHASE1 · RECRUITING· CTGOV
Publication
Combined Assessment of EZH2 and EGFR as Potential Diagnostic Biomarkers for Epithelial Ovarian Tumors: Bioinformatics Analysis and Clinical Validation.
19 Sept 2026· International journal of women's health· PUBMED
Publication
A Multiplex RT-QPCR Assay of ONECUT2, EZH2, and BRCA2 for the Detection of Clinically Significant Prostate Cancer in Needle Biopsies.
14 Sept 2026· Cancers· PUBMED
Publication
Effect of EZH2 regulation of the JAK2/STAT3 signaling pathway on proliferation and apoptosis in non‑small cell lung cancer cells.
11 Sept 2026· Oncology reports· PUBMED
Publication
Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity.
4 Sept 2026· Nature communications· PUBMED
Publication
Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance.
3 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.
29 Aug 2026· International journal of molecular sciences· PUBMED
Publication
EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study.
27 Aug 2026· Journal of clinical medicine· PUBMED
Publication
Retraction Note: DNA methylation of miR‑138 regulates cell proliferation and EMT in cervical cancer by targeting EZH2.
26 Aug 2026· BMC cancer· PUBMED
Publication
EZH2-dependent STAT3 stabilization drives pomalidomide resistance and is targetable by EZH2 inhibition in multiple myeloma.
26 Aug 2026· Acta biochimica et biophysica Sinica· PUBMED
Publication
Rethinking EZH2 Inhibition: A Priming Strategy for EGFR-targeted Therapy in Bladder Cancer.
25 Aug 2026· European urology oncology· PUBMED
Publication
Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage.
25 Aug 2026· Molecular therapy : the journal of the American Society of Gene Therapy· PUBMED
Publication
A biphasic hydrogel prevents glioblastoma recurrence by activating an EZH2-NeuroD1-SRCIN1 neuronal conversion axis.
19 Aug 2026· Biomaterials· PUBMED
Publication
FTO-mediated m6A demethylation of SNHG9 enhances PINK1-dependent mitophagy and reverses cisplatin resistance via nuclear EZH2 ubiquitination.
14 Aug 2026· Biochemical pharmacology· PUBMED
Preprint
Suppression of RIPK3 by EZH2 contributes to cigarette smoking-induced chemoresistance in lung cancer.
10 Aug 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Notch-1 induces M2 polarization of tumor-associated macrophages via the YAP/EZH2/FOXD1/CD47 signaling axis, thereby driving non-small cell lung cancer progression.
10 Aug 2026· Frontiers in medicine· PUBMED
Publication
Proximal tubular EZH2 inhibits diabetic kidney disease by suppressing SHC1-mediated oxidative stress.
10 Aug 2026· Free radical biology & medicine· PUBMED
Publication
Stage-dependent expression and nuclear localization of EZH2 in endometrial carcinogenesis: evidence from cell lines and human tissues.
7 Aug 2026· Journal of molecular histology· PUBMED

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error